This site uses cookies to provide a better browsing experience. More information can be found on our Privacy Policy page.

NodThera has changed its name to Rezera and announced a Phase 3 development program. Read Press Release

Newsroom

Stay informed on our latest company updates, scientific advancements, clinical milestones, and corporate announcements as we continue advancing NLRP3-based medicines.

Press Release

NodThera Appoints Geoff McDonough, M.D., as Independent Board Member
Press Release

NodThera Announces Appointment of Chris Guiffre, J.D., M.B.A., as Chief Financial Officer
Press Release

NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT- 0796 in Combination with a GLP-1 Receptor Agonist
Press Release

NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor
Press Release

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
Press Release

NodThera Announces Appointment of Elisabeth Björk as Board Member

Join Our Team